GPT Healthcare Limited GPTHEALTH NSEPHARMA

Healthcare · Medical Care Facilities · India

GPT Healthcare Limited owns and operates a chain of multispecialty hospitals under the ILS Hospitals brand name in India. The company offers healthcare services, including internal medicine and diabetology; nephrology, such as renal transplants; laparoscopic and general surgery; gynecology and obstetrics; critical care; gastroenterology; orthopedics and joint replacement; interventional cardiology; neurology; neurosurgery; pediatrics; neonatology; robotic-assisted surgery; bariatric surgery; hematology; psychology; dermatology; and ENT services. It also operates clinics and pharmacies; provides academic and diagnostic services; and sale of pharmaceutical products. The company was incorporated in 1989 and is based in Kolkata, India. GPT Healthcare Limited operates as a subsidiary of GPT Sons Pvt. Ltd.

Market & Price

Market Cap

₹1,168.46 Cr

Current Price

₹142.40

High / Low (52W)

₹181.88 / ₹115.31

Beta

0.49

Valuation

Stock P/E

27.65

Industry PE

37.60

Forward P/E

14.24

PEG Ratio

Book Value

₹30.88

Price to Book

4.61

P/S

2.47

EV/EBITDA

14.36

Dividend Yield

2.11%

Profitability & Returns

ROCE

16.36%

ROE

16.32%

ROA

8.41%

Profit Margin

8.94%

Op Margin

12.99%

EPS (Latest Qtr)

₹1.78

EPS (TTM)

₹5.15

Balance Sheet & Liquidity

Debt/Equity

0.34

Quick Ratio

0.92

Current Ratio

1.12

Debt

₹91.18 Cr

Total Assets

₹464.75 Cr

Current Assets

₹89.28 Cr

Working Capital

₹9.78 Cr

Ownership

Promoter Holding

65.57%

Chg in Prom Hold

FII / Inst Holding

7.45%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,209.04 Cr

Total Revenue (TTM)

₹472.55 Cr

EBITDA

₹84.18 Cr

Free Cash Flow

₹19.64 Cr

Operating Cash Flow

₹81.16 Cr

Shares Outstanding

₹8.21 Cr

Gross Margin

63.15%

Payout Ratio

48.54%

Growth (CAGR)

Revenue 5Y

9.45%

Profit 5Y

2.67%

Revenue (YoY)

24.60%

Earnings (YoY)

13.70%

PROS

Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GPTHEALTH GPT Healthcare Limited NSEPHARMA	142.40	27.65	₹1,168.46 Cr	2.11%	16.36%	16.32%	9.45%	2.67%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	102.21 Cr	101.40 Cr	107.11 Cr	118.91 Cr	120.16 Cr	126.37 Cr
Cost of Revenue	-	38.68 Cr	38.01 Cr	41.09 Cr	42.48 Cr	44.96 Cr	45.61 Cr
Gross Profit	-	63.52 Cr	63.39 Cr	66.02 Cr	76.42 Cr	75.20 Cr	80.76 Cr
Operating Expenses	-	46.93 Cr	47.57 Cr	54.83 Cr	60.53 Cr	61.60 Cr	64.34 Cr
Operating Income	-	16.59 Cr	15.82 Cr	11.18 Cr	15.89 Cr	13.60 Cr	16.42 Cr
EBITDA	-	23.14 Cr	22.26 Cr	18.93 Cr	24.08 Cr	22.13 Cr	25.00 Cr
Interest Expense	-	85.39 L	1.02 Cr	1.63 Cr	2.16 Cr	2.26 Cr	2.18 Cr
Pretax Income	-	17.62 Cr	16.37 Cr	11.11 Cr	15.07 Cr	12.76 Cr	15.86 Cr
Tax Provision	-	5.37 Cr	3.48 Cr	3.43 Cr	4.46 Cr	3.39 Cr	1.30 Cr
Net Income	-	12.25 Cr	12.89 Cr	7.68 Cr	10.60 Cr	9.37 Cr	14.57 Cr
Diluted EPS	1.81	1.49	1.57	0.94	1.29	1.14	1.78

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	360.39 Cr	399.55 Cr	407.09 Cr	472.55 Cr
Cost of Revenue	-	133.84 Cr	147.26 Cr	151.81 Cr	174.15 Cr
Gross Profit	-	226.55 Cr	252.29 Cr	255.28 Cr	298.39 Cr
Operating Expenses	-	167.11 Cr	180.23 Cr	190.96 Cr	241.30 Cr
Operating Income	-	59.44 Cr	72.06 Cr	64.32 Cr	57.09 Cr
EBITDA	-	79.32 Cr	92.52 Cr	91.85 Cr	90.13 Cr
Interest Expense	-	8.44 Cr	6.49 Cr	3.47 Cr	8.24 Cr
Pretax Income	-	55.97 Cr	68.04 Cr	69.35 Cr	54.81 Cr
Tax Provision	-	16.96 Cr	20.27 Cr	19.42 Cr	12.59 Cr
Net Income	-	39.01 Cr	47.77 Cr	49.92 Cr	42.22 Cr
Diluted EPS	-	4.75	5.96	6.08	5.15

Compounded Sales Growth

5 Years:	9.45%
1 Year:	24.60%

Compounded Profit Growth

5 Years:	2.67%
1 Year:	13.70%

Stock Price Performance

1 Year:	-5.13%
6 Months:	-1.04%
3 Months:	+13.93%
1 Month:	+5.09%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	326.76 Cr	345.52 Cr	384.25 Cr	464.75 Cr
Current Assets	-	81.27 Cr	80.16 Cr	78.82 Cr	89.28 Cr
Cash & Equivalents	-	6.60 Cr	1.69 Cr	1.66 Cr	4.13 Cr
Inventory	-	8.92 Cr	8.15 Cr	8.82 Cr	10.60 Cr
Receivables	-	20.68 Cr	24.28 Cr	19.70 Cr	20.28 Cr
Total Liabilities	-	161.40 Cr	127.03 Cr	136.40 Cr	195.32 Cr
Current Liabilities	-	81.84 Cr	77.21 Cr	74.24 Cr	79.49 Cr
Long Term Debt	-	40.27 Cr	3.62 Cr	5.53 Cr	7.16 Cr
Total Debt	-	82.36 Cr	30.54 Cr	35.30 Cr	91.18 Cr
Total Equity	-	165.36 Cr	218.49 Cr	247.85 Cr	269.43 Cr
Shares Outstanding	-	8.21 Cr	8.21 Cr	8.21 Cr	8.21 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	66.36 Cr	68.80 Cr	67.40 Cr	81.16 Cr
Investing Cash Flow	-	5.15 Cr	-25.21 Cr	-32.59 Cr	-47.25 Cr
Financing Cash Flow	-	-73.18 Cr	-48.50 Cr	-34.84 Cr	-31.43 Cr
Capital Expenditure	-	-9.95 Cr	-19.37 Cr	-49.93 Cr	-41.82 Cr
Free Cash Flow	-	56.41 Cr	49.43 Cr	17.47 Cr	39.34 Cr
Net Change in Cash	-	-1.67 Cr	-4.91 Cr	-3.44 L	2.47 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	62.9%	63.1%	62.7%	63.1%
Operating Margin %	-	16.5%	18.0%	15.8%	12.1%
Net Margin %	-	10.8%	12.0%	12.3%	8.9%
ROE %	-	23.6%	21.9%	20.1%	15.7%
ROCE %	-	24.3%	26.9%	20.7%	14.8%

Shareholding Pattern

Insiders

65.57%

Institutions

7.45%

Public Float

21.64%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GPTHEALTH

No recent headlines available.

GPTHEALTH · Healthcare